- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01217359
Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling
Purpose:
The purpose of this exploratory study is to evaluate phosphoprotein profiling to determine differences in the intracellular actions of interferon or interferon stimulated genes among people with different treatment outcomes to interferon based therapy for hepatitis C (HCV). Participants: Patients with genotype 1 HCV who have had interferon based therapy at the University of North Carolina (UNC). Procedures: Thirty patients with varied responses to treatment will be given a single subcutaneous injection of interferon alpha 2b. Prior to the injection and at 30 minutes, 1,2,4,6,12 and 20 hours after injection, blood will be drawn for analysis of phosphoprotein profiling and changes in serum cytokines.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To be eligible for this study, subjects must meet the following inclusion criteria:
- Willing and able to provide informed consent
- Males or females age 18 - 65 years
- For women of childbearing potential, negative blood pregnancy test documented within the 24-hour period prior to IFN-α administration
- History of genotype 1 HCV infection previously treated with peginterferon and ribavirin and with a virological response that can be determined from retrospective review of medical records
- A washout period of >12 weeks between the last dose of prescribed peginterferon and ribavirin and the screening visit
Exclusion Criteria
Subjects with any of the following will not be eligible for participation:
- Neutrophil count <1500 cells/mm3, Hgb <12 g/dL in women or 13 g/dL in men, or platelet count <75,000 cells/mm3 at screening
- Serum creatinine level >1.5 times the upper limit of normal at screening
- Poorly controlled psychiatric illness, as determined by the study physician, which can be exacerbated by interferon therapy
- Infection requiring antibiotics, symptomatic viral infection, inflammatory process requiring therapy, or allergic reactions in the week immediately preceding the inpatient study visit
- Use of medications that affect the immune system (e.g. glucocorticoids, chronic NSAIDs daily) in the week immediately preceding the inpatient study visit
- History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, psoriasis, rheumatoid arthritis)
- Women with ongoing pregnancy or breast-feeding
- History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
- History of a seizure disorder or current anticonvulsant use
- History of major organ transplantation with an existing functional graft
- History of thyroid disease poorly controlled on prescribed medications
- History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interferon Alfa-2b
Patients will receive a single dose of interferon
|
Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Protein quantification of interferon stimulated genes (ISG)
Time Frame: 0-20 hours
|
This is an exploratory study observing downstream phosphorylation of interferon stimulated genes in the Janus Activated Kinase (JAK-STAT) pathway.
|
0-20 hours
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sid Barritt, MD, MSCR, University of North Carolina, Chapel Hill
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Hepatitis
- Hepatitis C
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Interferons
- Interferon-alpha
- Interferon alpha-2
Other Study ID Numbers
- 08-2040
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
Sohag UniversityRecruiting
Clinical Trials on Interferon Alfa-2b
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)SuspendedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-ConfirmedUnited States
-
Merck Sharp & Dohme LLCTerminated
-
Brooke Army Medical CenterT.R.U.E. Research FoundationCompleted
-
St. Jude Children's Research HospitalSchering-PloughActive, not recruitingMalignant MelanomaUnited States
-
Columbia UniversityMerck Sharp & Dohme LLCWithdrawnEnd Stage Renal Disease | Hepatitis C Infection
-
Amsterdam UMC, location VUmcMerck Sharp & Dohme LLC; Novartis; Uppsala University HospitalTerminatedChronic Myeloid LeukemiaNetherlands, Denmark, Sweden, Finland, Norway
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingPrimary Myelofibrosis | Secondary MyelofibrosisUnited States
-
Merck Sharp & Dohme LLCTerminated
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)Completed
-
Emory UniversityCURE Childhood Cancer, Inc.CompletedJuvenile Pilocytic Astrocytomas | Optic Pathway GliomasUnited States